Renalytix Plc ( (RNLXY) ) has released its Q4 earnings. Here is a breakdown of the information Renalytix Plc presented to its investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Renalytix Plc is a pioneering company in the field of bioprognosis for kidney health, focusing on early-stage chronic kidney disease progression risk assessment through its FDA-approved KidneyIntelX.dkd platform. In its 2025 annual report, Renalytix highlighted significant achievements, including a 30% increase in total revenues and a 37% rise in commercial testing volumes, driven by Medicare reimbursement coverage and strategic partnerships. Key financial metrics showed a gross margin improvement to 40% and a 54% reduction in underlying EBITDA loss, attributed to operational efficiencies and cost management. Strategic collaborations with MVP Health Care and Tempus AI are set to expand the reach of KidneyIntelX.dkd, enhancing patient and physician access across the U.S. Looking forward, Renalytix aims to continue its growth trajectory by integrating its technology into electronic medical records, expanding insurance coverage, and pursuing international market opportunities.